Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

AstraZeneca

AstraZeneca secures US Approval for fixed-duration Calquence regimen in CLL

AstraZeneca’s Calquence plus venetoclax has been approved in the US as the first all-oral, 14-month treatment option for adults with CLL and SLL, following Phase III data showing improved progression-free survival versus chemoimmunotherapy...
Verici Dx

Verici Dx drives commercial growth, capturing US transplant market (LON:VRCI)

CEO Sara Barrington outlines Verici Dx’s commercial progress, reimbursement milestones, and expansion plans as the company scales its RNA-based kidney transplant test across the US...
Ethtry plc

Ethtry CEO Patrick Chopard on Strategy and Ethereum Treasury (AQSE:ETHY)

Ethtry CEO Patrick Chopard outlines Ethtry plc’s operating strategy, Ethereum treasury approach, and key partnerships supporting long-term value...
GSK

GSK secures EU approval for Exdensur in severe asthma and CRSwNP

GSK announced European Commission approval of Exdensur (depemokimab) as an add-on treatment for severe asthma with type 2 inflammation in patients aged 12 and older, and for adults with severe chronic rhinosinusitis with nasal polyps...
Aptamer

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system...
Verici Dx Plc

Verici Dx revenue growth signals commercial inflection point

Rising Tutivia adoption and broader US insurance coverage are strengthening revenue visibility and commercial positioning...
EDX Medical Group plc

EDX Medical raises £3.5m to accelerate prostate cancer programme

EDX Medical Group plc has completed a £3.5 million fundraising from existing high net worth shareholders, issuing 24,999,999 new ordinary shares at 14p per share...
Brava Health

Brava Health positions for the next phase of digital care integration

Brava Health is building patient-controlled digital infrastructure to simplify how people organise and act on their health information...
Aptamer Group

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows...

Verici Dx: Tutivia Set to Disrupt Transplant Monitoring with Real-Time RNA Insights (Video)

Tutivia is turning heads in transplant care. Verici Dx CEO Sara Barrington explains how their RNA-based rejection test is setting new standards in real-world use—and why clinicians and payers are getting on board...
AstraZeneca

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial execution and pipeline progress...
GSK

GSK receives EU approval for Nucala in Eosinophilic COPD

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils...
Brava Health

Brava Health CMO urges human-centred approach to MedTech

Brava Health’s CMO calls on the MedTech industry to align innovation with clinical responsibility at a key industry event...
Verici Dx Plc

Verici Dx delivers FY25 growth as Tutivia™ commercialisation accelerates

For the year ended 31 December 2025, Verici Dx Plc reported unaudited revenues of $3.8m, driven by first recognised Tutivia™ revenues, increased test volumes, and expanded US reimbursement coverage...
Verici Dx

Verici Dx secures BCBS Illinois agreement for Tutivia kidney transplant test

Verici Dx Plc has entered into an agreement with Blue Cross and Blue Shield of Illinois to provide in-network coverage for Tutivia™, its post-kidney transplant diagnostic test...
Oxford Biomedica Plc

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes...
GSK

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV...
Cizzle Bio

Cizzle Biotechnology secures Canadian patent for CIZ1B lung cancer test

Cizzle Biotechnology has been granted Canadian patent protection for methods measuring the CIZ1B lung cancer biomarker, strengthening its intellectual property portfolio...
AstraZeneca

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure...
Brava Health

Delay damages patients, and the system pays for it

In joint surgery, delays don’t just postpone care, they increase risk, reduce recovery and raise long-term cost...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

October 23, 2024

AstraZeneca

AstraZeneca secures US Approval for fixed-duration Calquence regimen in CLL

AstraZeneca’s Calquence plus venetoclax has been approved in the US as the first all-oral, 14-month treatment option for adults with CLL and SLL, following Phase III data showing improved progression-free survival versus chemoimmunotherapy...
Verici Dx

Verici Dx drives commercial growth, capturing US transplant market (LON:VRCI)

CEO Sara Barrington outlines Verici Dx’s commercial progress, reimbursement milestones, and expansion plans as the company scales its RNA-based kidney transplant test across the US...
Ethtry plc

Ethtry CEO Patrick Chopard on Strategy and Ethereum Treasury (AQSE:ETHY)

Ethtry CEO Patrick Chopard outlines Ethtry plc’s operating strategy, Ethereum treasury approach, and key partnerships supporting long-term value...
GSK

GSK secures EU approval for Exdensur in severe asthma and CRSwNP

GSK announced European Commission approval of Exdensur (depemokimab) as an add-on treatment for severe asthma with type 2 inflammation in patients aged 12 and older, and for adults with severe chronic rhinosinusitis with nasal polyps...
Aptamer

Aptamer and Metir advance real-time water pathogen detection programme

Aptamer Group has met Phase 1 technical objectives in its partnership with Metir, demonstrating the feasibility of integrating Optimer® binders into a continuous waterborne pathogen detection system...
Verici Dx Plc

Verici Dx revenue growth signals commercial inflection point

Rising Tutivia adoption and broader US insurance coverage are strengthening revenue visibility and commercial positioning...
EDX Medical Group plc

EDX Medical raises £3.5m to accelerate prostate cancer programme

EDX Medical Group plc has completed a £3.5 million fundraising from existing high net worth shareholders, issuing 24,999,999 new ordinary shares at 14p per share...
Brava Health

Brava Health positions for the next phase of digital care integration

Brava Health is building patient-controlled digital infrastructure to simplify how people organise and act on their health information...
Aptamer Group

Aptamer technology integrated into Twist’s new TrueAmp NGS Library Prep Kit

Aptamer Group has announced that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit, incorporating Aptamer’s proprietary Optimer® binders to enable room-temperature stability in next-generation sequencing workflows...

Verici Dx: Tutivia Set to Disrupt Transplant Monitoring with Real-Time RNA Insights (Video)

Tutivia is turning heads in transplant care. Verici Dx CEO Sara Barrington explains how their RNA-based rejection test is setting new standards in real-world use—and why clinicians and payers are getting on board...
AstraZeneca

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial execution and pipeline progress...
GSK

GSK receives EU approval for Nucala in Eosinophilic COPD

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils...
Brava Health

Brava Health CMO urges human-centred approach to MedTech

Brava Health’s CMO calls on the MedTech industry to align innovation with clinical responsibility at a key industry event...
Verici Dx Plc

Verici Dx delivers FY25 growth as Tutivia™ commercialisation accelerates

For the year ended 31 December 2025, Verici Dx Plc reported unaudited revenues of $3.8m, driven by first recognised Tutivia™ revenues, increased test volumes, and expanded US reimbursement coverage...
Verici Dx

Verici Dx secures BCBS Illinois agreement for Tutivia kidney transplant test

Verici Dx Plc has entered into an agreement with Blue Cross and Blue Shield of Illinois to provide in-network coverage for Tutivia™, its post-kidney transplant diagnostic test...
Oxford Biomedica Plc

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes...
GSK

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV...
Cizzle Bio

Cizzle Biotechnology secures Canadian patent for CIZ1B lung cancer test

Cizzle Biotechnology has been granted Canadian patent protection for methods measuring the CIZ1B lung cancer biomarker, strengthening its intellectual property portfolio...
AstraZeneca

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure...
Brava Health

Delay damages patients, and the system pays for it

In joint surgery, delays don’t just postpone care, they increase risk, reduce recovery and raise long-term cost...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple